1. Figure S1 0 1 2 3 4 UV- UV+ Relative expression levels of rhoB mRNA by qRT-PCR *

2. 28S 18S tRNA UV-UV+ : 60J/m2 input 12345678910111213141516171234567891011121314151617 Figure S2 0 2 4 6 8 10 12 14 1234567891011121314151617 % of actin mRNA in each fraction fractions % of rhoB mRNA levels in each fraction fractions

3. 012 012 Figure S3 Relative luciferase activity (Rluc/FLuc) RLuc rhoB 3’UTR RLuc P53 3’UTR Donor 1Donor 2 0 10 20 30 40 mockmiR- 19b (2 nM) Figure S4 Relative levels of miR-19b by qRT-PCR Transfection: ***

4. Figure S5 0 0.4 0.8 1.2 U6snRNARNU44RNU48 0 0.4 0.8 1.2 U6snRNA RNU44RNU48 Normalization: Relative levels of indicated miRNA by qRT-PCR miR-18amiR-92 0 0.4 0.8 U6snRNARNU44RNU48 0 0.4 0.8 1.2 U6snRNARNU44RNU48 miR-30amiR-30cmiR-30e miR-21miR-223miR-183 0 0.4 0.8 1.2 U6snRNARNU44RNU48 U6snRNARNU44RNU48U6snRNARNU44RNU48 0 0.4 0.8 0 0.4 0.8 0 0.4 0.8 1 U6snRNA RNU44 RNU48 UV- UV+

5. Figure S6 Amount of rhoB mRNA in crosslinked IP (qRT-PCR) 0 2 4 6 8 10 12 UV- UV+ IP HuR ** IP Igg1

6. Figure S7  HuR (3A2) Igg mouse DAPIFITC No UV  HuR (3A2) Igg mouse UVC (60 J/m 2 ) Merge

7. Tubulin HuR Topoisomerase I - + - + UV: Nuc. Cyto. 37 50 100 kDa 68 hnRNP C1 / C2 CFI 68 39 Figure S8 b a Amount of rhoB mRNA in IP (qRT-PCR) 0 2 4 6 8 10 12 UV- UV+ IP HuR ** IP Igg1

8. RhoB actin HuR UV: +-+-+- siHuRsiHuR’siCtrl Figure S9

9. 0 5 10 15 20 25 30 IP Igg1 IP HuR UV+ Figure S10 Amount of rhoB mRNA in IP (qRT-PCR) Mock miR-19 * * IP Ago2 * * 35

10. b TUNEL – positive cells (% of total cells) (after UV treatment) 0102030405060 Mock miR-24 miR-19b siRhoB Figure S11 a Mock miR-24 miR-19b siRhoB DAPI TUNEL DAPI TUNEL UV-UV+ ** *

11. Table S1 Log-Fold-Change Log-Odds miR-1297 -0.9277974 2.100182 miR-943 1.1359647 3.980016 miR-33a -1.0995417 2.613077 miR-92b* 1.3969320 3.268697 miR-576-5p -1.0307652 2.339584 miR-520c-3p -0.8056853 2.109405 miR-1-2-as -1.2286145 2.469158 miR-1291 -1.1521645 2.189155 miR-1186 -1.2878478 3.899560 miR-673-3p 1.4335437 2.874723 UV regulated miRNAs according to the miRNA microarray results

12. Table S2 Foward R everse 3’UTR rhoB5’GCTCTAGAAAGGTGCTATG AGGGCCG 3' 5’CGGGATCCCGGAGTTGGCAAGA AAGGATCT 3' 3’UTR p535’CAGACTAGTTGACTCAGAC TGACATTCT 3‘ 5’GCTAGATCTTGGCAGCAAAGTTT TATTGTA 3’ 3’UTR rhoB mut miR- 19 5’TTTGTTTTTTTATTCTTTCGA GAATTGTTTCATTGTTTGACA CTT 3’ 5’AAGTGTCAAACAATGAAACAATT CTCGAAAGAATAAAAAAACAAA 3’ 3’UTR rhoB mut-HuR5’CTGATGTTATTTGATTTAAG AAAAGGCTAAAATTTG 3’ 5’CAAATTTTAGCCTTTTCTTAAATC AAATAACATCAG 3’ 3’UTR rhoB  34-418 5’GCTCTCGAGTCTGAAGAGC CGGGCCT 3’ 5’GGACTCGAGTGCCGGCAGGGG CAGG 3’ 3’UTR rhoB  34-878 5’TGCTCTCGAGTTGACACTTA ATGCACTCGT 3’ 5’GGACTCGAGTGCCGGCAGGGG CAGG 3’ 3’UTR rhoB  34- 1088 5’GCTCTCGAGTAAAGGGCAG TAACAAGTATTG 3‘ 5’GGACTCGAGTGCCGGCAGGGG CAGG 3’ 3’UTR rhoB  1109- 1285 5’GCTCTCGAGTGACAAAATG GTGAGCTTATG 3’ 5’GCTCTCGAGTGACAAAATGGTG AGCTTATG 3‘ 3’UTR rhoB  778- 1285 5’GCTCTCGAGTGACAAAATG GTGAGCTTATG 3’ 5’GCTCTCGAGCAGGCACAAAGTT CGCTTAT 3‘ Sequences of oligonucleotides used for mutagenesis and cloning

13. Table S3 siHuR5’-AAGAGGCAATTACCAGTTTCA-3’ (Kawai et al., 2006) siHuR’Pool of 5’-AATCTTAAGTTTCGTAAGTTA-3’ 5’-TTCGTAAGTTATTTCCTTTAA-3’ 5’-TTCCTTTAAGATATATATTAA-3’ (Gorospe et al., 2008) siCtrl5’-ACUCUAUCUGCACGCUGACUU-3’ Sequences of siRNAs used in this study. Kawai et al., Mol Cell Biol. (2006) 26(8):3295-307. Galban et al., Mol Cell Biol. (2008) 28(1):93-107

14. Table S4 RhoB Forward5’-GTGCCTGCTGATCGTGTTC-3’ RhoB Reverse 5’-GCGGTCGTAGTCCTCCTG-3’ Beta-actin Forward 5’-CCTCGCCTTTGCCGATCCG-3’ Beta-actin Reverse 5’-ATGCCGGAGCCGTTGTCG-3’ p53 Forward 5’-GTGGTGGTGCCCTATGAG-3’ p53 Forward 5’-GAGTCTTCCAGTGTGATGATG-3’ GAPDH Forward 5’-TGCACCACCAACTGCTTAGC-3’ GAPDH Reverse5’-GGCATGGACTGTGGTCATGAG-3’ RLuc Forward 5’-TGGTAACGCGGCCTCTTC-3’ RLuc Reverse 5’-ATTTGCCTGATTTGCCCATAC-3’ FLuc Forward 5’-GGATGGAACCGCTGGAGAG-3’ Fluc Reverse 5’-GCTTCTGCCAACCGAACG-3’ Sequences of primers used for RTqPCR experiments